RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia

Trial Profile

RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders; Myocardial ischaemia; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms RESOLUTE Asia
  • Sponsors Medtronic
  • Most Recent Events

    • 09 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 02 May 2012 Actual patient number added 312 according to ClinicalTrials.gov.
    • 02 May 2012 Planned End Date changed from 1 Aug 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top